Cargando…
131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Mathematical models have predicted that targeted radiotherapy of neuroblastoma with metaiodobenzylguanidine (mIBG) is less likely to cure small rather than large micrometastases if 131I is the conjugated radionuclide. This study uses multicellular tumour spheroids as an in vitro model to test the hy...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978020/ https://www.ncbi.nlm.nih.gov/pubmed/1457344 |
_version_ | 1782135387650523136 |
---|---|
author | Gaze, M. N. Mairs, R. J. Boyack, S. M. Wheldon, T. E. Barrett, A. |
author_facet | Gaze, M. N. Mairs, R. J. Boyack, S. M. Wheldon, T. E. Barrett, A. |
author_sort | Gaze, M. N. |
collection | PubMed |
description | Mathematical models have predicted that targeted radiotherapy of neuroblastoma with metaiodobenzylguanidine (mIBG) is less likely to cure small rather than large micrometastases if 131I is the conjugated radionuclide. This study uses multicellular tumour spheroids as an in vitro model to test the hypothesis that smaller tumours of sub-millimetre dimensions are relatively resistant to 131I-mIBG. Spheroids of the human neuroblastoma cell line SK-N-BE(2c), either 250 microns or 400 microns diameter, were incubated with 131I-mIBG at concentrations of up to 6.0 MBq ml-1. Using both regrowth delay and spheroid 'cure' as endpoints, the greater vulnerability of larger spheroids was confirmed. From this in vitro result we conclude that when used in vivo 131I-mIBG may spare smaller micrometastases. Therefore, either a radionuclide such as 211At which emits a shorter path length radiation should be conjugated to mIBG, or targeted radiotherapy should be combined with a treatment such as total body irradiation, the efficacy of which is not reduced in smaller tumours. |
format | Text |
id | pubmed-1978020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1992 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19780202009-09-10 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Gaze, M. N. Mairs, R. J. Boyack, S. M. Wheldon, T. E. Barrett, A. Br J Cancer Research Article Mathematical models have predicted that targeted radiotherapy of neuroblastoma with metaiodobenzylguanidine (mIBG) is less likely to cure small rather than large micrometastases if 131I is the conjugated radionuclide. This study uses multicellular tumour spheroids as an in vitro model to test the hypothesis that smaller tumours of sub-millimetre dimensions are relatively resistant to 131I-mIBG. Spheroids of the human neuroblastoma cell line SK-N-BE(2c), either 250 microns or 400 microns diameter, were incubated with 131I-mIBG at concentrations of up to 6.0 MBq ml-1. Using both regrowth delay and spheroid 'cure' as endpoints, the greater vulnerability of larger spheroids was confirmed. From this in vitro result we conclude that when used in vivo 131I-mIBG may spare smaller micrometastases. Therefore, either a radionuclide such as 211At which emits a shorter path length radiation should be conjugated to mIBG, or targeted radiotherapy should be combined with a treatment such as total body irradiation, the efficacy of which is not reduced in smaller tumours. Nature Publishing Group 1992-12 /pmc/articles/PMC1978020/ /pubmed/1457344 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Gaze, M. N. Mairs, R. J. Boyack, S. M. Wheldon, T. E. Barrett, A. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. |
title | 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. |
title_full | 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. |
title_fullStr | 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. |
title_full_unstemmed | 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. |
title_short | 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. |
title_sort | 131i-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978020/ https://www.ncbi.nlm.nih.gov/pubmed/1457344 |
work_keys_str_mv | AT gazemn 131imetaiodobenzylguanidinetherapyinneuroblastomaspheroidsofdifferentsizes AT mairsrj 131imetaiodobenzylguanidinetherapyinneuroblastomaspheroidsofdifferentsizes AT boyacksm 131imetaiodobenzylguanidinetherapyinneuroblastomaspheroidsofdifferentsizes AT wheldonte 131imetaiodobenzylguanidinetherapyinneuroblastomaspheroidsofdifferentsizes AT barretta 131imetaiodobenzylguanidinetherapyinneuroblastomaspheroidsofdifferentsizes |